In contrast, CCR7− cDC1s further contribute to the acquisition of the CD8+ T cell effector programme and support their tumoricidal activity through the secretion of IL‐12, contributing to productive anti‐cancer immunity [48]. The gene discussed is CD8A; the disease is cancer.